Scholars Central

Conference abstract

Targeted nano-based proteostasis-inhibition for controlling lung cancer pathogenesis and progression

Authors: Neeraj Vij, Changhoon Ji

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

We recently identified valosin-containing protein (VCP)/p97-retrograde translocation as a novel proteostasis mechanism involved in non-small cell lung cancer (NSCLC) pathogenesis and progression. Since VCP is involved in homeostatic processes (proteostasis), we developed a nano-based targeted proteostasis-inhibitor delivery system for targeting lung tumors as a novel selective proteostasis-inhibition strategy to control NSCLC progression and metastasis. We identified that the PLGA-PEG based bio-degradable nanoparticles (NPs) are safer for selective molecular targeting of proteostasis-inhibitor over polymeric chitosan-dextran sulphate (CS-DS; p<0.02; 24hrs) NPs as they did not inhibit non-tumor lung epithelial (Beas2b) cell proliferation. We encapsulated potent VCP-proteostasis-inhibitor (N 2, N 4 -dibenzylquinazoline-2, 4-diamine; DBeQ) in PLGA-PEG (PLGA-PEG DBeQ ) NPs for targeted release of the drug without affecting the non-tumor cells. Next, we standardized the efficacy of PLGA-PEG DBeQ NPs (~15μM) to control NSCLC growth and progression. We found that PLGA-PEG DBeQ NPs significantly inhibit NSCLC migration (n=6, p<0.001; 24hrs) and proliferation (n=6, p<0.03; 24hrs & p<0.002; 48hrs) while inducing apoptosis (n=5, p<0.01; 48hrs). Moreover, we evaluated the anti-proliferative, apoptotic and tumor inhibitory efficacy of PLGA-PEG DBeQ NPs in athymic-nude mice (n=6; xenograft-model) injected with GeltrexTM-H1299 (4x10 6; day-0) tumors. We observed that PLGA-PEG DBeQ NPs (~15μM; day-10) induce anti-tumor activity within 48hrs, as seen by significant (p<0.005; day- 12) reduction in tumor sizes (~1.44-fold), without any significant body weight loss. The data demonstrates the safety and efficacy of novel PLGA-PEG based selective proteostasis-inhibition strategy (PLGA-PEG DBeQ ) for lung cancer therapy PDF HTML

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Nanomedicine & Nanotechnology.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Nanomedicine & Nanotechnology
  • SubjectNanotechnology
  • BylineArticles whose byline prints “Neeraj Vij”
  • BylineArticles whose byline prints “Changhoon Ji”